New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
Clinical and Molecular Hepatology
;
: 115-121, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-128622
ABSTRACT
Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Compuestos de Fenilurea
/
Vena Porta
/
Quimioembolización Terapéutica
/
Niacinamida
/
Terapia Combinada
/
Carcinoma Hepatocelular
/
Trombosis de la Vena
/
Inhibidores de Proteínas Quinasas
/
Neoplasias Hepáticas
Tipo de estudio:
Guía de Práctica Clínica
Límite:
Humanos
Idioma:
Inglés
Revista:
Clinical and Molecular Hepatology
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS